Developing and manufacturing vaccines for infectious diseases
Official title: Task V26: The Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of services spanning product development planning and
Funded at Advanced Bioscience Laboratories, INC. · NIH-10168819 · Data updated 2026-11-12
This study is all about creating and improving new vaccines to help protect people from infectious diseases, making sure they meet safety standards, so that patients can benefit from better protection against illnesses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Advanced Bioscience Laboratories, INC. NIH-funded |
| Lab location | 1 site (Kensington, United States) |
| Project start | May 15, 2018 |
| Project end | May 14, 2028 |
| Funding year | 2020 |
| Award (this year) | $29,859 |
| NIH project number | 272201800009I-0-759302000002-1 |
| Project ID | NIH-10168819 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals at risk for infectious diseases or those involved in clinical trials for new vaccines.
✕Less likely to help
Patients with established immunity to the targeted infectious diseases or those not at risk for such diseases may not receive direct benefits from this research.
What this research studies
This research focuses on providing essential services for the development and manufacturing of vaccines and biologics aimed at combating infectious diseases. It includes planning and feasibility assessments, product optimization, and compliant manufacturing for early-phase clinical studies. The project also involves conducting technical audits and providing regulatory support to ensure that new vaccines meet FDA standards. Patients may benefit from the introduction of new vaccines that protect against emerging infectious threats.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective vaccines that protect patients from infectious diseases and bioterrorism threats.
How similar studies have gone: Other research has shown success in developing vaccines using similar methodologies, indicating a promising approach to vaccine development.
Where this research is happening
-
Advanced Bioscience Laboratories, INC.
Kensington, United States Active
Researchers
- Principal investigator: Fouts, Tim — Advanced Bioscience Laboratories, INC.
- Study coordinator: Fouts, Tim
Related research
Other NIH-funded projects on the same topics.
-
Development of vaccines and biologics for infectious diseases
This study is working on creating new vaccines to help protect people from infectious diseases, and it aims to make sure these vaccines are safe and effective before they are approved for use.
-
Developing new vaccines and biologics for infectious diseases
This study is all about creating and improving vaccines to help protect people from tough infections, including those that are hard to treat and could be used in bioterrorism, so that patients can have better options for staying healthy.
-
Developing a vaccine to fight fungal infections
This study is working on a new vaccine to help protect people, especially those with weakened immune systems, from serious fungal infections like Candida auris and Cryptococcus neoformans, which can be tough to treat.
-
Identifying and testing a new antibody treatment for Duchenne Muscular Dystrophy.
This study is looking at a new treatment for Duchenne Muscular Dystrophy (DMD) using a special type of antibody, and it aims to make sure the drug is safe and works well before it can be tested in people like you.
-
Developing and testing new oligonucleotides for medical use
This study is working on creating new types of medicines that target specific genes, which could lead to better treatments for patients with various health conditions.
-
Manufacturing a new treatment for pain management
This study is exploring a new way to help manage pain using a special compound called VHCA8*, and it's designed for people looking for better pain relief options that are safe and backed by science.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.